Phillips Edison & Company Announces Appointment of Anthony “Tony” Terry to Board of Directors
CINCINNATI, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of...
Read moreDetailsPlasticizers Market to Reach USD 21.8 Bn in 2032, Driven by Rising Demand For Flexible PVC in Expanding End-Uses & Applications
Marketresearch.biz reports that the Plasticizers Market thrives by enhancing plastic flexibility in construction, automotive, and healthcare sectors. Increasing demand for...
Read moreDetailsMagnesium Acetate Market revenue to reach USD 15 Million by 2035, says Research Nester
Major Magnesium Acetate Market players include Merck KGaA, American Elements, Celtic Chemicals, Niacet Corporation, Hefei TNJ Chemical Industry, VASA PharmaChem,...
Read moreDetailsLoop-mediated Isothermal Amplification (LAMP) Market revenue to cross USD 180 Million by 2033, says Research Nester
Major Loop-mediated Isothermal Amplification (LAMP) Market players include Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., New England Biolabs, Inc., Nippon Gene...
Read moreDetailsPassage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on...
Read moreDetailsEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
Landmark cardiac xenotransplantation procedure conducted at University of Maryland Medical Center Tegoprubart, administered investigationally to prevent organ rejection post-transplant, targets...
Read moreDetailsNear Intelligence’s Board Grows Stronger with Key Appointments
Sherman Edmiston III and Richard J. Salute bring extensive technology, accounting, and business expertise to Near’s Board of DirectorsPASADENA, Calif.,...
Read moreDetailsClene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8® 30mg...
Read moreDetailsVoyager Therapeutics to Present at the Chardan Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through...
Read moreDetailsHilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Read moreDetailsADVERTISEMENTS
Latest Posts
- Bitcoin could hit $1 million by early 2027, study finds April 19, 2025
- Soybeans Speculative Net Positions Swing Positive Amid Market Optimism April 18, 2025
- CFTC Reports Significant Rise in Corn Speculative Net Positions to 234.2K April 18, 2025
- New Zealand Dollar Speculators Cut Bearish Bets as NZD Positions Improve April 18, 2025
- Surge in Japanese Yen Speculative Positions as CFTC Reports Significant Increase April 18, 2025